What Happened?
Toronto, ON-based Ripple Therapeutics Promoted Wendy Naimark as Chief Technology Officer
Date of management change: January 15, 2021
Toronto, ON-based Ripple Therapeutics Promoted Wendy Naimark as Chief Technology Officer
The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.
Wendy Naimark is Chief Technology Officer at Ripple Therapeutics. Previously, Wendy held various senior IT leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: K. Daniel, Veum Eric, Nair Kesavan, Serrano Michael, Ainsworth Gareth, Rodehorst Mike, Lacourse Brandyn, Owens Georgina, Stone David, Behar Meron, Dave Jayesh
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.